As the attorneys at Levin & Perconti recently blogged about, European and American drug regulators reacted to data on weightloss/obesity drug Meridia recently. Now, the FDA’s decision is causing controversy as it starkly differs from European regulator’s decision. The New York Times addressed that raw data from the drug study indicated that people with certain health problems who took the prescription diet drug Meridia experienced more heart attacks, strokes, and other cardiovascular problems.
Last week, the European regulating body advised physicians and pharmacists to cease prescribing and dispensing the European equivalent of Meridia. In contrast, the Food and Drug Administration took a less forceful step and just asked the maker of Meridia to put a stronger warning on its label. The significantly different actions by two health authorities is stirring debate among drug makers and consumer advocates.
Click here to read more about the controversy surrounding the Meridia decision.